TY - JOUR
T1 - Chronic graft-versus-host disease following umbilical cord blood transplantation
T2 - Retrospective survey involving 1072 patients in Japan
AU - Narimatsu, Hiroto
AU - Miyakoshi, Shigesaburo
AU - Yamaguchi, Takuhiro
AU - Kami, Masahiro
AU - Matsumura, Tomoko
AU - Yuji, Koichiro
AU - Murashige, Naoko
AU - Kusumi, Eiji
AU - Kodama, Yuko
AU - Komatsu, Tsunehiko
AU - Sakamaki, Hisashi
AU - Kouzai, Yasushi
AU - Okada, Masaya
AU - Osugi, Yuko
AU - Kobayashi, Ryoji
AU - Inoue, Masami
AU - Takahashi, Satoshi
AU - Kai, Shunro
AU - Kato, Koji
AU - Inoue-Nagamura, Tokiko
AU - Taniguchi, Shuichi
AU - Kato, Shunichi
PY - 2008/9/15
Y1 - 2008/9/15
N2 - We have little information on chronic graft-versus-host disease (GVHD) after cord blood transplantation (CBT). We investigated its clinical features in 1072 Japanese patients with hematologic malignancies who received a transplant through the Japan Cord Blood Bank Network. The primary end point was to investigate the incidence of any chronic GVHD. Median age of the patients was 33 years (range, 0-79 years). The cumulative incidence of chronic GVHD 2 years after transplantation was 28%. Chronic GVHD was fatal in 29 patients. Multivariate analysis demonstrated that development of chronic GVHD was favorably associated with both overall survival and event-free survival. Multivariate analysis identified risk factors of chronic GVHD: higher patient body weight, higher number of mismatched antigens for GVHD direction, myeloablative preparative regimen, use of mycophenolate mofetil in GVHD prophylaxis, and development of grades II to IV acute GVHD. Although chronic GVHD is a significant problem after CBT, it is associated with improved survival, perhaps due to graft-versus-malignancy effects.
AB - We have little information on chronic graft-versus-host disease (GVHD) after cord blood transplantation (CBT). We investigated its clinical features in 1072 Japanese patients with hematologic malignancies who received a transplant through the Japan Cord Blood Bank Network. The primary end point was to investigate the incidence of any chronic GVHD. Median age of the patients was 33 years (range, 0-79 years). The cumulative incidence of chronic GVHD 2 years after transplantation was 28%. Chronic GVHD was fatal in 29 patients. Multivariate analysis demonstrated that development of chronic GVHD was favorably associated with both overall survival and event-free survival. Multivariate analysis identified risk factors of chronic GVHD: higher patient body weight, higher number of mismatched antigens for GVHD direction, myeloablative preparative regimen, use of mycophenolate mofetil in GVHD prophylaxis, and development of grades II to IV acute GVHD. Although chronic GVHD is a significant problem after CBT, it is associated with improved survival, perhaps due to graft-versus-malignancy effects.
UR - http://www.scopus.com/inward/record.url?scp=55249121453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55249121453&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-11-118893
DO - 10.1182/blood-2007-11-118893
M3 - Article
C2 - 18559675
AN - SCOPUS:55249121453
SN - 0006-4971
VL - 112
SP - 2579
EP - 2582
JO - Blood
JF - Blood
IS - 6
ER -